MarketCap
Facebook
X
Telegram
iBio Market Cap | IBIO
As of October 06, 2026 iBio has a market cap of $ 117 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap iBio
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 142 M | 60.6 M | 7.55 M | 177 K | 22.2 M | - | 294 M | 13.1 M | 8.72 M | 27.6 M | 50.2 M | 46.5 M | 24.6 M | 24.7 M | 46.6 M | 83.3 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 294 M | 177 K | 56.7 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Avidity Biosciences
RNA
|
10 B | $ 7.97 | 1.66 % | $ 1.1 B |  USA |
 |
Royalty Pharma plc
RPRX
|
18.9 B | $ 56.66 | 0.36 % | $ 24.4 B | USA |
 |
Revolution Medicines
RVMD
|
19.6 B | $ 207.68 | 0.5 % | $ 39.5 B | USA |
 |
Rhythm Pharmaceuticals
RYTM
|
6.34 B | $ 92.45 | 0.24 % | $ 6.01 B | USA |
 |
Rezolute
RZLT
|
409 M | $ 4.33 | 7.98 % | $ 450 M | USA |
 |
Sana Biotechnology
SANA
|
995 M | $ 2.88 | 1.21 % | $ 729 M | USA |
 |
Seer
SEER
|
123 M | $ 2.33 | 3.56 % | $ 129 M | USA |
 |
SIGA Technologies
SIGA
|
404 M | $ 3.48 | 2.96 % | $ 249 M | USA |
 |
Sol-Gel Technologies Ltd.
SLGL
|
203 M | $ 78.95 | 9.65 % | $ 220 M |  Israel |
|
Silence Therapeutics plc
SLN
|
812 M | $ 10.14 | 0.78 % | $ 1.44 B |  Britain |
 |
SELLAS Life Sciences Group
SLS
|
567 M | $ 11.63 | 3.62 % | $ 1.27 B | USA |
 |
Summit Therapeutics
SMMT
|
12 B | $ 17.27 | 3.07 % | $ 12.9 B | Britain |
 |
Syndax Pharmaceuticals
SNDX
|
1.73 B | $ 17.83 | 1.31 % | $ 1.54 B | USA |
 |
Soligenix
SNGX
|
6.12 M | $ 0.36 | 0.6 % | $ 1.87 M | USA |
 |
Sanofi
SNY
|
59.3 B | $ 39.51 | 1.19 % | $ 48.2 B |  France |
 |
Spruce Biosciences
SPRB
|
47.6 M | $ 45.42 | 2.1 % | $ 34.8 M | USA |
 |
Spero Therapeutics
SPRO
|
133 M | $ 1.16 | 4.13 % | $ 65 M | USA |
 |
Sarepta Therapeutics
SRPT
|
1.64 B | $ 17.49 | 0.7 % | $ 1.75 B | USA |
 |
Scholar Rock Holding Corporation
SRRK
|
5.09 B | $ 43.4 | 1.41 % | $ 4.98 B | USA |
 |
Stoke Therapeutics
STOK
|
2.01 B | $ 25.32 | 0.8 % | $ 1.5 B | USA |
 |
Sutro Biopharma
STRO
|
181 M | $ 15.13 | 0.23 % | $ 129 M | USA |
 |
Shattuck Labs
STTK
|
349 M | $ 6.5 | 1.04 % | $ 452 M | USA |
 |
Supernus Pharmaceuticals
SUPN
|
3.11 B | $ 42.76 | 0.9 % | $ 2.41 B | USA |
 |
Sesen Bio
SESN
|
26.1 M | - | 7.29 % | $ 127 M | USA |
 |
Savara
SVRA
|
1.17 B | $ 4.78 | 0.1 % | $ 1.06 B | USA |
 |
China SXT Pharmaceuticals
SXTC
|
1.14 M | $ 2.08 | 1.99 % | $ 1.41 M |  China |
 |
Takeda Pharmaceutical Company Limited
TAK
|
23.8 B | $ 17.81 | 0.08 % | $ 28.1 B |  Japan |
|
Protara Therapeutics
TARA
|
245 M | $ 2.63 | 0.36 % | $ 113 M | USA |
 |
Tarsus Pharmaceuticals
TARS
|
2.92 B | $ 74.46 | 1.99 % | $ 3.11 B | USA |
 |
Bio-Techne Corporation
TECH
|
11.3 B | $ 72.58 | 0.25 % | $ 11.3 B | USA |
 |
Tenax Therapeutics
TENX
|
569 M | $ 1.96 | 2.59 % | $ 76.9 M | USA |
 |
Teva Pharmaceutical Industries Limited
TEVA
|
41.3 B | $ 39.66 | 0.33 % | $ 45.4 B | Israel |
 |
TG Therapeutics
TGTX
|
4.34 B | $ 53.91 | 0.12 % | $ 7.78 B | USA |
 |
Tonix Pharmaceuticals Holding Corp.
TNXP
|
114 M | $ 8.07 | 0.54 % | $ 68.7 M | USA |
 |
Trevi Therapeutics
TRVI
|
1.51 B | $ 13.72 | 0.99 % | $ 1.85 B | USA |
 |
Taysha Gene Therapies
TSHA
|
1.46 B | $ 4.49 | 0.11 % | $ 1.44 B | USA |
 |
UroGen Pharma Ltd.
URGN
|
924 M | $ 42.78 | 3.33 % | $ 2.06 B | Israel |
 |
United Therapeutics Corporation
UTHR
|
23.6 B | $ 536.4 | 0.37 % | $ 23.8 B | USA |
 |
Vericel Corporation
VCEL
|
1.88 B | $ 41.07 | 2.29 % | $ 2.07 B | USA |
 |
Veracyte
VCYT
|
3.04 B | $ 47.67 | 4.06 % | $ 3.75 B | USA |
 |
Vir Biotechnology
VIR
|
1.02 B | $ 11.78 | 5.46 % | $ 1.63 B | USA |
 |
Viking Therapeutics
VKTX
|
3.18 B | $ 29.28 | 0.36 % | $ 3.3 B | USA |
 |
Vanda Pharmaceuticals
VNDA
|
358 M | $ 4.58 | 0.51 % | $ 270 M | USA |
 |
Verrica Pharmaceuticals
VRCA
|
66.7 M | $ 4.31 | 0.21 % | $ 45.9 M | USA |
 |
Vertex Pharmaceuticals Incorporated
VRTX
|
125 B | $ 503.5 | 0.07 % | $ 129 B | USA |
 |
Verastem
VSTM
|
404 M | $ 8.0 | 3.9 % | $ 554 M | USA |
 |
VistaGen Therapeutics
VTGN
|
21.7 M | $ 0.26 | 0.21 % | $ 9.9 M | USA |
 |
vTv Therapeutics
VTVT
|
67.6 M | $ 30.33 | 0.59 % | $ 120 M | USA |
 |
Voyager Therapeutics
VYGR
|
241 M | $ 2.46 | 0.41 % | $ 144 M | USA |
 |
Wave Life Sciences Ltd.
WVE
|
2.6 B | $ 3.75 | 0.66 % | $ 632 M |  Singapore |